CLBAX
Price
$40.85
Change
+$0.21 (+0.52%)
Updated
Jul 6 closing price
Net Assets
287.61B
FBLAX
Price
$13.59
Change
-$0.01 (-0.07%)
Updated
Jul 6 closing price
Net Assets
3.46B
Interact to see
Advertisement

CLBAX vs FBLAX

CLBAX vs FBLAX Comparison Chart in %
View a ticker or compare two or three
VS
CLBAX vs. FBLAX commentary
Jul 07, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLBAX is a Buy and FBLAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CLBAX has more cash in the bank: 288B vs. FBLAX (3.46B). FBLAX pays higher dividends than CLBAX: FBLAX (4.31) vs CLBAX (1.79). CLBAX was incepted earlier than FBLAX: CLBAX (24 years) vs FBLAX (20 years). FBLAX (0.91) is less costly to investors than CLBAX (0.58). CLBAX is a more actively managed with annual turnover of: 50.00 vs. FBLAX (42.27). FBLAX initial investment is less costly to investors than CLBAX (4%) vs CLBAX (4%). CLBAX has a lower initial minimum investment than FBLAX: CLBAX (250) vs FBLAX (1000). CLBAX annual gain was more profitable for investors over the last year : 13.21 vs. FBLAX (12.46). CLBAX return over 5 years is better than : 36.60 vs. FBLAX (21.01).
CLBAXFBLAXCLBAX / FBLAX
Total Expense Ratio0.580.9164%
Annual Report Gross Expense Ratio0.580.9164%
Fund Existence24 years20 years-
Gain YTD9.8297.100138%
Front Load4%6%64%
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets288B3.46B8,319%
Annual Yield % from dividends1.794.3141%
Returns for 1 year13.2112.46106%
Returns for 3 years44.6929.53151%
Returns for 5 years36.6021.01174%
Returns for 10 years95.9158.10165%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IAG16.56N/A
N/A
IAMGold Corp
XRPNU10.91N/A
N/A
Armada Acquisition Corp. II
PN3.88N/A
N/A
PN Smart Energy Limited
TACO10.52N/A
N/A
Berto Acquisition Corp
GLUE24.21N/A
N/A
Monte Rosa Therapeutics